09:59 AM EST - ProMIS Neurosciences : Announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates for Alzheimer's disease (AD) blocked propagation of toxic, prion-like forms of Amyloid beta (AĆ) in vitro. ProMIS Neurosciences
shares T.PMN are trading unchanged at $0.14.
